Stifel Reiterates Reiterates Sage Therapeutics (SAGE) at Buy, Zuranolone is An Approvable Product, But Durability of Benefit and Commercial Positioning Remain Debatable
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating on Sage Therapeutics (NASDAQ: SAGE), following the readout of CORAL trial results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
